Standard Article

New Drugs and Nutraceuticals in the Treatment of Osteoarthritis

Development of Therapeutic Agents Handbook

  1. Y. Henrotin,
  2. J.-Y. Reginster

Published Online: 16 DEC 2011

DOI: 10.1002/9780470571224.pse454

Pharmaceutical Sciences Encyclopedia

Pharmaceutical Sciences Encyclopedia

How to Cite

Henrotin, Y. and Reginster, J.-Y. 2011. New Drugs and Nutraceuticals in the Treatment of Osteoarthritis. Pharmaceutical Sciences Encyclopedia. 37.

Author Information

  1. Institute of Pathology, University of Liège, Bone and Cartilage Research Unit, Liège, Belgium

Publication History

  1. Published Online: 16 DEC 2011


Osteoarthritis is a disease with a multifactorial etiology affecting all joint tissues and involving both biochemical and mechanical factors that act in synergy to degrade cartilage. Until now, OA treatments are limited to pain relief, even if some new drugs of the SYSADOA class have shown potential structure-modifying effects. These drugs target cartilage as the endpoint of joint failure, underestimating the role played by subchondral bone and synovium in this process. However, recent studies emphasized the key role played by subchondral bone sclerosis and synovium inflammation in OA pathophysiology. Unfortunately, until now, there is no validated method for a reliable assessment of structural changes in these tissues, explaining that guidance documents edited by the official agencies and scientific societies are strictly focused on the assessment of cartilage changes.


  • osteoarthritis;
  • subchondral bone sclerosis;
  • synovium inflammation;
  • methylsulfonylmethane (MSM);
  • nutraceuticals